Kyverna Therapeutics stock upgraded to Strong Buy after positive phase 2 results for miv-cel in SPS and MG. Read the latest ...
November jobs growth surprised to the upside at 64,000, with private payrolls at 69,000. Learn more about BLS report here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback